124 related articles for article (PubMed ID: 18631948)
1. One-week dose titration of extended release galantamine in patients with Alzheimer's disease.
Scharre DW; Shiovitz T; Zhu Y; Amatniek J
Alzheimers Dement; 2008 Jan; 4(1):30-7. PubMed ID: 18631948
[TBL] [Abstract][Full Text] [Related]
2. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
Dunbar F; Zhu Y; Brashear HR
Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
[TBL] [Abstract][Full Text] [Related]
3. [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].
Blesa R; García Ribas G; Galdós L; Olascoaga J; Amer G; Marey López J; Barquero M; Marsall C; Ezpeleta D
Neurologia; 2006; 21(6):289-96. PubMed ID: 16799903
[TBL] [Abstract][Full Text] [Related]
4. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
5. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.
Senanarong V; Poungvarin N; Phanthumchinda K; Thavichachart N; Chankrachang S; Praditsuwan R; Nidhinandana S
J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S12-8. PubMed ID: 19562980
[TBL] [Abstract][Full Text] [Related]
7. The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.
Chankrachang S; Senanarong V; Poungvarin N; Phanthumchinda K; Tavichachart N; Praditsuwan R; Nidhinandana S
J Med Assoc Thai; 2008 Sep; 91(9):1343-9. PubMed ID: 18843862
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.
Hing JP; Piotrovsky V; Kimko H; Brashear HR; Zhao Q
Curr Med Res Opin; 2005 Apr; 21(4):483-8. PubMed ID: 15899095
[TBL] [Abstract][Full Text] [Related]
9. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Edwards K; Royall D; Hershey L; Lichter D; Hake A; Farlow M; Pasquier F; Johnson S
Dement Geriatr Cogn Disord; 2007; 23(6):401-5. PubMed ID: 17409748
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.
Edwards KR; Hershey L; Wray L; Bednarczyk EM; Lichter D; Farlow M; Johnson S
Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():40-8. PubMed ID: 14676468
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.
Yao C; Raoufinia A; Gold M; Nye JS; Ramael S; Padmanabhan M; Walschap Y; Verhaeghe T; Zhao Q
J Clin Pharmacol; 2005 May; 45(5):519-28. PubMed ID: 15831775
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
Isik AT; Bozoglu E; Naharci MI; Kilic S
Am J Geriatr Pharmacother; 2010 Oct; 8(5):454-9. PubMed ID: 21335298
[TBL] [Abstract][Full Text] [Related]
14. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
15. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
16. Galantamine-associated nightmares and anxiety.
Corbo JM; Brown JN; Moss JM
Consult Pharm; 2013 Apr; 28(4):243-6. PubMed ID: 23552705
[TBL] [Abstract][Full Text] [Related]
17. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
19. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
Cummings JL; Schneider L; Tariot PN; Kershaw PR; Yuan W
Am J Psychiatry; 2004 Mar; 161(3):532-8. PubMed ID: 14992980
[TBL] [Abstract][Full Text] [Related]
20. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations.
Piotrovsky V; Van Peer A; Van Osselaer N; Armstrong M; Aerssens J
J Clin Pharmacol; 2003 May; 43(5):514-23. PubMed ID: 12751272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
